• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
An Example of Ovarian Cancer as a 'Chronic Disease Process' - 11-Year Survival with Multiple Treatments for Recurrent and Progressive Disease.
Case Rep Oncol. 2008 Oct 17;1(1):1-4. doi: 10.1159/000164683.
2
Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer.总生存期和疾病进展后生存期是晚期或复发性上皮性卵巢癌二线/三线化疗Ⅲ期试验中的有效终点指标。
J Cancer. 2018 Feb 16;9(5):872-879. doi: 10.7150/jca.17664. eCollection 2018.
3
The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.对于晚期原发性和复发性上皮性卵巢癌患者，低位前侧整块切除作为肿瘤细胞减灭术的一部分，其益处超过了对发病率的担忧。
Gynecol Oncol. 2006 Dec;103(3):977-84. doi: 10.1016/j.ygyno.2006.06.004. Epub 2006 Jul 11.
4
Medical therapy of advanced malignant epithelial tumours of the ovary.晚期卵巢恶性上皮性肿瘤的医学治疗
Forum (Genova). 2000 Oct-Dec;10(4):323-32.
5
Survival of patients with advanced and recurrent ovarian cancer treated using integrative medicine in Malaysia: A case series.马来西亚采用整合医学治疗晚期和复发性卵巢癌患者的生存情况：病例系列研究。
Complement Ther Clin Pract. 2019 Nov;37:73-85. doi: 10.1016/j.ctcp.2019.09.001. Epub 2019 Sep 6.
6
A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.腹腔内热灌注化疗（HIPEC）治疗晚期和复发性卵巢癌的评价。
Gynecol Oncol. 2015 Jan;136(1):130-5. doi: 10.1016/j.ygyno.2014.11.072. Epub 2014 Nov 28.
7
Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature.晚期上皮性卵巢癌的二次手术细胞减灭术。患者选择及文献综述。
Cancer. 1996 Nov 15;78(10):2049-62.
8
Surgical treatment pattern and outcomes in epithelial ovarian cancer patients from a cancer institute in Kerala, India.印度喀拉拉邦一家癌症研究所上皮性卵巢癌患者的手术治疗模式及结果
Ecancermedicalscience. 2016 Feb 4;10:619. doi: 10.3332/ecancer.2016.619. eCollection 2016.
9
Medical treatment of resistant or recurrent epithelial ovarian cancer.耐药或复发性上皮性卵巢癌的医学治疗。
Ann Oncol. 2006 Jun;17 Suppl 7:vii49-50. doi: 10.1093/annonc/mdl950.
10
A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.预测贝伐珠单抗联合化疗治疗复发性卵巢癌女性总生存期的列线图。
Gynecol Oncol. 2014 Mar;132(3):531-6. doi: 10.1016/j.ygyno.2014.01.036. Epub 2014 Jan 25.

引用本文的文献

1
Openness and topic avoidance in interpersonal communication about ovarian cancer: An uncertainty management perspective.卵巢癌人际沟通中的开放性与话题回避：不确定性管理视角
Qual Res Med Healthc. 2022 Jan 31;5(3):9376. doi: 10.4081/qrmh.2021.9376. eCollection 2021 Dec 31.

本文引用的文献

1
Pharmaceutical management of ovarian cancer : current status.卵巢癌的药物治疗：现状
Drugs. 2008;68(6):771-89. doi: 10.2165/00003495-200868060-00004.
2
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.吉西他滨联合卡铂与卡铂治疗铂敏感复发性卵巢癌患者的比较：AGO-OVAR、NCIC CTG和EORTC GCG的一项组间试验
J Clin Oncol. 2006 Oct 10;24(29):4699-707. doi: 10.1200/JCO.2006.06.0913. Epub 2006 Sep 11.
3
Viewing ovarian cancer as a "chronic disease": what exactly does this mean?将卵巢癌视为“慢性病”：这究竟意味着什么？
Gynecol Oncol. 2006 Feb;100(2):229-30. doi: 10.1016/j.ygyno.2005.08.043. Epub 2005 Oct 14.
4
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.卵巢癌中铂类和紫杉烷耐药记录后的生存情况：一项涉及多项2期临床试验的单机构经验。
Gynecol Oncol. 2004 Jun;93(3):699-701. doi: 10.1016/j.ygyno.2004.03.023.
5
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.紫杉醇联合铂类化疗与传统铂类化疗用于复发性卵巢癌女性的疗效比较：ICON4/AGO-OVAR-2.2试验
Lancet. 2003 Jun 21;361(9375):2099-106. doi: 10.1016/s0140-6736(03)13718-x.
6
Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer?
Gynecol Oncol. 2001 Dec;83(3):449-50. doi: 10.1006/gyno.2001.6458.
7
Second-line treatment of ovarian cancer.卵巢癌的二线治疗
Oncologist. 2000;5(1):26-35. doi: 10.1634/theoncologist.5-1-26.
8
Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature.晚期上皮性卵巢癌的二次手术细胞减灭术。患者选择及文献综述。
Cancer. 1996 Nov 15;78(10):2049-62.
9
Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer.纪念斯隆凯特琳癌症中心按照美国国立癌症研究所治疗转诊中心9103方案接受治疗的患者随访：紫杉醇用于难治性卵巢癌
J Clin Oncol. 1996 Mar;14(3):796-9. doi: 10.1200/JCO.1996.14.3.796.

An Example of Ovarian Cancer as a 'Chronic Disease Process' - 11-Year Survival with Multiple Treatments for Recurrent and Progressive Disease.

作者信息

Markman Maurie, Malviya Vinay

机构信息

The University of Texas M.D. Anderson Cancer Center, Houston, Tex., and Division of Gynecologic Oncology, Providence Cancer Center, Detroit, Mich., USA.

出版信息

Case Rep Oncol. 2008 Oct 17;1(1):1-4. doi: 10.1159/000164683.

DOI:10.1159/000164683
PMID:20212914
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2811868/
Abstract

The 11-year survival of a woman with recurrent progressive advanced epithelial ovarian cancer emphasizes the potential for the disease process to be quite 'chronic' in nature.

摘要